First Time Loading...

ReShape Lifesciences Inc
NASDAQ:RSLS

Watchlist Manager
ReShape Lifesciences Inc Logo
ReShape Lifesciences Inc
NASDAQ:RSLS
Watchlist
Price: 0.1698 USD -4.61% Market Closed
Updated: Apr 28, 2024

Wall Street
Price Targets

RSLS Price Targets Summary
ReShape Lifesciences Inc

Wall Street analysts forecast RSLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RSLS is 1 USD .

Lowest
Price Target
Not Available
Average
Price Target
1 USD
489% Upside
Highest
Price Target
Not Available
ReShape Lifesciences Inc Competitors:
Price Targets
MLAB
Mesa Laboratories Inc
29% Upside
7716
Nakanishi Inc
37% Upside
TNDM
Tandem Diabetes Care Inc
4% Upside
IPD
ImpediMed Ltd
113% Upside
2216
Broncus Holding Corp
183% Upside
688161
Shandong Weigao Orthopaedic Device Co Ltd
170% Upside
041830
InBody Co Ltd
29% Upside
RMD
Resmed Inc
5% Downside

Revenue
Forecast

Revenue Estimate
ReShape Lifesciences Inc

For the last 8 years the compound annual growth rate for ReShape Lifesciences Inc's revenue is 10%. The projected CAGR for the next 2 years is 19%.

10%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
ReShape Lifesciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
ReShape Lifesciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-100%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RSLS's stock price target?
Price Target
1 USD

According to Wall Street analysts, the average 1-year price target for RSLS is 1 USD .

What is ReShape Lifesciences Inc's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for ReShape Lifesciences Inc's revenue is 10%. The projected CAGR for the next 2 years is 19%.